MesenCult™-SF Attachment Substrate

Serum-free attachment substrate for human mesenchymal stem cells
概要
MesenCult™-SF Attachment Substrate is a serum-free substrate for the in vitro culture of human mesenchymal stem and progenitor cells (MSCs). The substrate supports both expansion of human MSCs in vitro as well as their enumeration using the colony forming unit–fibroblast (CFU-F) assay.
Cell Type
Mesenchymal Stem and Progenitor Cells
Species
Human
Brand
MesenCult
技术资料
Document Type 产品名称 Catalog # Lot # 语言
Product Information Sheet MesenCult™-SF Attachment Substrate 05424 All English
Safety Data Sheet MesenCult™-SF Attachment Substrate 05424 All English
数据及文献

Publications (1)

Frontiers in immunology 2019 Pneumococcal Polysaccharide Vaccine Ameliorates Murine Lupus. C. Cantarelli et al.

Abstract

Current guidelines encourage administering pneumococcal vaccine Prevnar-13 to patients with lupus, but whether such vaccinations affect disease severity is unclear. To address this issue, we treated 3-month-old MRL-lpr mice, that spontaneously develop a lupus-like syndrome, with Prevnar-13 or vehicle control. After 3 months, we quantified circulating anti-Pneumococcal polysaccharide capsule (PPS) antibodies and signs of disease severity, including albuminuria, renal histology and skin severity score. We also compared immunophenotypes and function of T and B cells from treated and untreated animals. Prevnar-13 elicited the formation of anti-pneumococcal IgM and IgG. Prevnar-13 treated animals showed reduced albuminuria, renal histological lesions, and milder dermatitis compared to vehicle-treated controls. Mitigated disease severity was associated with reduced and increased T follicular helper cells (TFH) and T follicular regulatory cells (TFR), respectively, in Prevnar-treated animals. T cells from Prevnar-13 vaccinated mice showed differential cytokine production after aCD3/aCD28 stimulation, with significantly decreased IL-17 and IL-4, and increased IL-10 production compared to non-vaccinated mice. In conclusion, pneumococcal vaccination elicits anti-pneumococcal antibody response and ameliorates disease severity in MRL-lpr mice, which associates with fewer TFH and increased TFR. Together, the data support use of Prevnar vaccination in individuals with SLE.
View All Publications
Top